Miklos Palotai

List of Publications by Year
in descending order

36 papers	579 citations	471061 17 h-index	676716 22 g-index
40 all docs	40 docs citations	40 times ranked	890 citing authors

#	Article	IF	Citations
1	Magnetic resonance elastography to study the effect of amyloid plaque accumulation in a mouse model. Journal of Neuroimaging, 2022, , .	1.0	2
2	Aquaporin 4 distribution in the brain and its relevance for the radiological appearance of neuromyelitis optica spectrum disease. Journal of Neuroradiology, 2021, 48, 170-175.	0.6	4
3	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. NeuroImage: Clinical, 2021, 30, 102659.	1.4	3
4	Microstructural Changes in the Left Mesocorticolimbic Pathway are Associated with the Comorbid Development of Fatigue and Depression in Multiple Sclerosis. Journal of Neuroimaging, 2021, 31, 501-507.	1.0	7
5	Usability of a Mobile App for Real-Time Assessment of Fatigue and Related Symptoms in Patients With Multiple Sclerosis: Observational Study. JMIR MHealth and UHealth, 2021, 9, e19564.	1.8	9
6	Targeted Blood Brain Barrier Opening With Focused Ultrasound Induces Focal Macrophage/Microglial Activation in Experimental Autoimmune Encephalomyelitis. Frontiers in Neuroscience, 2021, 15, 665722.	1.4	6
7	The effects of CRF and the urocortins on the hippocampal acetylcholine release in rats. Neuropeptides, 2021, 88, 102147.	0.9	1
8	Identification and Characterization of Leptomeningeal Metastases Using SPINE, A Webâ€Based Collaborative Platform. Journal of Neuroimaging, 2021, 31, 324-333.	1.0	3
9	Brain anatomical correlates of fatigue in multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 751-764.	1.4	38
10	Microstructural fronto-striatal and temporo-insular alterations are associated with fatigue in patients with multiple sclerosis independent of white matter lesion load and depression. Multiple Sclerosis Journal, 2020, 26, 1708-1718.	1.4	25
11	Magnetic Resonance Elastography reveals effects of anti-angiogenic glioblastoma treatment on tumor stiffness and captures progression in an orthotopic mouse model. Cancer Imaging, 2020, 20, 35.	1.2	11
12	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. Journal of Neurology, 2020, 267, 3541-3554.	1.8	14
13	A novel classification of fatigue in multiple sclerosis based on longitudinal assessments. Multiple Sclerosis Journal, 2020, 26, 725-734.	1.4	13
14	Perivascular Unit: This Must Be the Place. The Anatomical Crossroad Between the Immune, Vascular and Nervous System. Frontiers in Neuroanatomy, 2020, 14, 17.	0.9	46
15	History of fatigue in multiple sclerosis is associated with grey matter atrophy. Scientific Reports, 2019, 9, 14781.	1.6	24
16	Changes in striatal dopamine release and locomotor activity following acute withdrawal from chronic nicotine are mediated by CRF1, but not CRF2, receptors. Brain Research, 2019, 1706, 41-47.	1.1	8
17	Imaging localized neuronal activity at fast time scales through biomechanics. Science Advances, 2019, 5, eaav3816.	4.7	32
18	Characterization of glioblastoma in an orthotopic mouse model with magnetic resonance elastography. NMR in Biomedicine, 2018, 31, e3840.	1.6	25

#	Article	IF	Citations
19	Changes to the septo-fornical area might play a role in the pathogenesis of anxiety in multiple sclerosis. Multiple Sclerosis Journal, 2018, 24, 1105-1114.	1.4	23
20	Evaluating the Association between Enlarged Perivascular Spaces and Disease Worsening in Multiple Sclerosis. Journal of Neuroimaging, 2018, 28, 273-277.	1.0	24
21	Cover image, Volume 31 Issue 10. NMR in Biomedicine, 2018, 31, e3825.	1.6	0
22	Large deep neural networks for MS lesion segmentation. Proceedings of SPIE, 2017, , .	0.8	0
23	Anxiolytic effect of the GPR103 receptor agonist peptide P550 (homolog of neuropeptide 26RFa) in mice. Involvement of neurotransmitters. Peptides, 2016, 82, 20-25.	1.2	6
24	Selective CRF2 receptor agonists ameliorate the anxiety- and depression-like state developed during chronic nicotine treatment and consequent acute withdrawal in mice. Brain Research, 2016, 1652, 21-29.	1.1	22
25	Fatigue predicts disease worsening in relapsing-remitting multiple sclerosis patients. Multiple Sclerosis Journal, 2016, 22, 1841-1849.	1.4	41
26	The action of neuropeptide AF on passive avoidance learning. Involvement of neurotransmitters. Neurobiology of Learning and Memory, 2016, 127, 34-41.	1.0	7
27	Neuropeptide AF induces anxiety-like and antidepressant-like behavior in mice. Behavioural Brain Research, 2014, 274, 264-269.	1.2	25
28	The action of orexin B on passive avoidance learning. Involvement of neurotransmitters. Behavioural Brain Research, 2014, 272, 1-7.	1.2	20
29	Interleukin-1Î² (187â€"207)-Induced Hyperthermia is Inhibited by Interleukin-1Î² (193â€"195) in Rats. Neurochemical Research, 2014, 39, 254-258.	1.6	0
30	Involvement of Neurotransmitters in the Action of the Nociceptin/Orphanin FQ Peptide-Receptor System on Passive Avoidance Learning in Rats. Neurochemical Research, 2014, 39, 1477-1483.	1.6	3
31	The effect of urocortin I on the hypothalamic ACTH secretagogues and its impact on the hypothalamic-pituitary-adrenal axis. Neuropeptides, 2014, 48, 15-20.	0.9	18
32	The actions of neuropeptide SF on the hypothalamicâ€"pituitaryâ€"adrenal axis and behavior in rats. Regulatory Peptides, 2014, 188, 46-51.	1.9	10
33	Orexin A-induced anxiety-like behavior is mediated through GABA-ergic, Î±- and Î²-adrenergic neurotransmissions in mice. Peptides, 2014, 57, 129-134.	1.2	24
34	Ghrelin and Nicotine Stimulate Equally the Dopamine Release in the Rat Amygdala. Neurochemical Research, 2013, 38, 1989-1995.	1.6	21
35	Ghrelin amplifies the nicotine-induced dopamine release in the rat striatum. Neurochemistry International, 2013, 63, 239-243.	1.9	33
36	The interaction of Urocortin II and Urocortin III with amygdalar and hypothalamic cotricotropin-releasing factor (CRF) â€" Reflections on the regulation of the hypothalamicâ€"pituitaryâ€"adrenal (HPA) axis. Neuropeptides, 2013, 47, 333-338.	0.9	25